Updated efficacy and safety data from IMbrave150: Atezolizumab Dr. Li on the Subgroup Analysis of the IMbrave150 Trial in Older Patients With HCC
Daneng Li, MD, of City of Hope National Medical Center, Duarte, CA, discusses results from older adults enrolled in IMbrave150 IMBrave150 Regimen: Managing Varices
An expert clinical review of data from the EGFR-mutated subset included in the IMpower-150 trial looking at the addition of Dr. Galle on Patient-Reported Outcomes From the Phase III IMbrave150 Trial Bradley G. Somer, MD, discusses the impact of the phase 3 IMbrave150 trial on the treatment of patients with unresectable
Checkpoint inhibition in hepatocellular carcinoma Dr. Somer on the Impact of the IMbrave150 Trial on the HCC Paradigm
IMbrave150 Trial: Combination Therapy in Advanced HCC Richard Kim, MD, on the outcome on the IMBRAVE 150 study & the possibility of new treatment standard Richard S. Finn, MD, tells us about the safety profile of atezolizumab & bevacizumab from IMbrave150
Impact of IMbrave150 on theadvanced HCC treatment landscape: How dose it improve patient outcomes? 7/1/2021. ASCO GI 2021: trial updates
Dr. Vijayvergia, Assistant Professor of Hematology and Oncology, Assistant Chief of GI Medical Oncology, Fox Chase Cancer Prof Richard Finn speaks to ecancer in an online interview for the virtual AACR 2021 meeting about the updated safety and
IMbrave150 Phase III Design, Results, and Practical Implications Philippe Merle, MD, PhD, Croix-Rousse Hospital, Lyon, France, updates on key trials that wil be presented at this years upcoming New Options for Overcoming Resistance to Anti-VEGF Therapy in HCC
Depth and Duration of Response Are Associated with Survival in 2021 TASL HCC Single Topic Conference Satellite symposium - Roche Impact of IMbrave150 on theadvanced HCC treatment In this animated video article, we present the phase III HIMALAYA study, which investigated tremelimumab and durvalumab for
Michael Lee, MD, of UNC Lineberger Cancer Center, Chapel Hill, NC, explains the efficacy and safety results for atezolizumab IMpower-150: EGFR-Mutated Subset Analysis Introduction. The IMbrave150 study of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC)
Patient-Reported Outcomes Improve with Combination Treatment for Patients With HCC First-line treatment options for advanced HCC including sorafenib, lenvatinib, and atezolizumab-bevacizumab as systemic HCC podcast series part 1: The use of IO in unresectable HCC
To our knowledge, IMbrave150 was the first phase 3 trial since 2007 to show a significant and clinically meaningful survival benefit with Pierce Chow, MBBS, MMed (Surg), FRCS (Edin), FAMS (Gen Surg), PhD, National Cancer Centre Singapore & Duke-NUS
Peter R. Galle, MD, PhD, Johannes Gutenberg University, Mainz, Germany, shares updated efficacy data from the Phase III IMbrave150 in Unresectable HCC David J. Pinato, MD, PhD, clinical senior lecturer in medical oncology, clinician scientist, and consultant medical oncologist in the
Impact of IMbrave150 Trial: APAC Expert Review Now Published An influx of treatments are emerging against hepatocellular carcinoma (HCC), a common malignancy with huge unmet needs, Mehmet Akce, MD, an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of
Shahid Ahmed, PhD, MD, FRCPC, FACP, Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Canada, provides IMbrave150 analysis. Oncologist. 2025 Sep 1;30(9):oyaf269. doi: 10.1093 IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Namrata Vijayvergia, MD, discusses updates from the IMbrave150 trial as presented at ASCO GI 2021
ASCO GI: updates in KEYNOTE-177, IMbrave150 & ClarIDHy Jawaban Webinar 5 Years of IMbrave150 - Milestones and Future Opportunities in HCC #Dokter #nilai100
Advanced HCC: IMbrave150 Trial Peter R. Galle, MD, the director of the Medical Department at the University Medical Center Mainz and president-elect of the IMbrave150: The first successful Phase III trial of a cancer
Dra. Renata D'Alpino, Oncologista Clínica do Grupo Oncoclínicas e Diretora Científica do Grupo Brasileiro de Tumores Key updates from ASCO GI 2021
Full Podcast: Experts provide an overview of current systemic treatment options for 1st line uHCC, Dr. Kaubisch on Treatment Options for HCC
Atezolizumab and bevacizumab for upfront unresectable HCC IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly improved overall survival (OS) and progression-free survival (PFS) compared Richard S. Finn, MD, discusses the significance of the results presented on the recent IMbrave150 study in unresectable
Wasif M. Saif, MD, deputy physician in chief at the Northwell Health Cancer Institute and a professor at the Donald and Barbara Updates from IMbrave 150 in HCC Addressing How to Treat Patients With Advanced Hepatocellular Carcinoma
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma Richard S. Finn, MD, considers whether updated results from IMbrave150 are practice-changing
Dr. Kaseb, Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, on the In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the Patient-reported outcomes with atezolizumab plus bevacizumab
Ahmed Kaseb, MD, on survival outcomes in the IMBRAVE 150 phase 3 study Real-world experience of Impower150 regimen for EGFR+ NSCLC
IMbrave150: Updated overall survival (OS) data from a global Daneng Li, MD, on impressions of patient reported outcomes from the IMBRAVE 150 study
The IMpower150 study (NCT02366143) showed that atezolizumab in combination with bevacizumab, carboplatin, and paclitaxel AACR 2021: Dra. Renata D'Alpino aborda a análise do estudo IMbrave150
We met up with Dr Michel Ducreux at ESMO 2018 who provided a brief review of the current treatment landscape for Combination Atezolizumab Plus Bevacizumab Improved Quality of Life in HCC
With Prof. Jean-François Dufour about this journal paper: "Efficacy and Safety of Atezolizumab plus Bevacizumab versus Dr. Kim, Professor of Medicine, Moffit Cancer Center, describes the IMBRAVE 150 phase 3 study and whether the overall survival TECENTRIQ, in combination with bevacizumab, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC)
This exploratory analysis reports efficacy and safety results in patients with baseline Barcelona Clinic Liver Cancer (BCLC) stage B disease. James J. Harding, MD, regional director of Early Drug Development at Memorial Sloan Kettering Cancer Center, discusses the Daneng Li, MD, discusses the subgroup analysis of the phase 3 IMbrave150 trial in patients with unresectable hepatocellular
Dr. Harding on the Goal of the IMbrave150 trial in HCC Dr.Molham Khalil.
Ghassan K. Abou-Alfa, MD, MBA, leads a discussion on the management of varices occurring in patients with metastatic IMbrave150: updated data on atezo plus bev versus sorafenib in HCC Ask the author session with Prof. Michel Ducreux
Experts provide an overview of current systemic treatment options for 1st line uHCC, discussing the role of IO and IO-based An overview of the IMbrave150 phase III trial data as they relate to the management of hepatocellular carcinoma.
Richard S. Finn, MD, regarding the updated IMbrave150 data from ASCO GI 2021 IMbrave050: adjuvant atezolizumab with bevacizumab in high-risk HCC
IMbrave150: updated overall survival data from a global The role of sorafenib in the first-line treatment of HCC as seen in the IMbrave150 trial. For more resources and information
A video summary of the HIMALAYA study PLSP: Tremelimumab and Durvalumab for Unresectable HCC Upcoming IO combinations for advanced HCC IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab
Dr Katie Kelley talks to ecancer in an online interview for the ASCO virtual meeting 2020 about using durvalumab and Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of immune Study Details | NCT03434379 | A Study of Atezolizumab in
Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma Synergy of anti-androgenic agents and immune checkpoint inhibitors in HCC IMbrave150 showed consistent clinically meaningful treatment benefit and safety with 12 mo of additional follow-up.
Daniel Catenacci, MD, University of Chicago, Chicago, IL, provides an overview of some of the exciting data presented at this Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the Phase III HIMALAYA trial which investigated
Dr. Li, Assistant Clinical Professor, City of Hope, shares his impressions of the IMBRAVE 150 study particularly relating to patient The use of Immunotherapy (IO) in unresectable Hepatocellular Carcinoma (HCC) A review of the phase 3 IMbrave150 trial comparing atezolizumab-bevacizumab vs standard of care, sorafenib, as initial therapy
Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal IMbrave150 Phase III Trial for MHCC
Andreas Kaubisch, MD, associate attending physician, Montefiore Medical Center, Albert Einstein College of Medicine, discusses Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Michel Ducreux, MD, PhD, of the Gustave Roussy Institute, Villejuif, France, explores the emerging synergistic mechanisms of
When compared to Nexavar (sorafenib) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), Exploring Current and Upcoming Therapies for Hepatocellular Carcinoma
The IMbrave150 trial showed significantly better overall survival and progression-free survival outcomes with atezolizumab plus bevacizumab than HIMALAYA: Does underlying liver function impact efficacy of tremelimumab plus durvalumab for HCC?
Additionally, an exploratory analysis of the patients with Vp4 HCC (15%) enrolled on the IMbrave-150 trial also demonstrated improved efficacy Michel Ducreux, ESMO 2018 – Exploring new treatment options for hepatocellular carcinoma IMbrave150 Trial: Frontline Treatment of Advanced HCC
HIMALAYA and IMbrave-150 for Hepatocellular Carcinoma: A Treatment of advanced HCC IMbrave - 150 trail || علاج HCC IMbrave المتقدم An overview of the phase III IMbrave150 trial, inclusion criteria, primary/secondary end points, and practical implications. Website:
• Here, we report updated efficacy data for IMbrave150 with 12 mo of additional follow-up (median follow-up: 15.6 mo). Page 3. Study design. Key eligibility.